Tolerance of anticoagulation in hereditary hemorrhagic telangiectasia

Despite being a hemorrhagic condition, patients with hereditary hemorrhagic telangiectasia (HHT) are at increased thromboembolic risk. We designed an observational retrospective cohort study of HHT patients who required anticoagulation therapy, described their indications and adverse events. From January 2006 until August 2019 28 out of 347 adult HHT patients received anticoagulant drugs for a median of 0.5  years (IQR 0.2–4.1). Median age was 64 years (IQR 51–70), all of the patients had epistaxis and at least one arteriovenous malformation.

Source: Thrombosis Research - October 19, 2020 Category: Hematology Authors: Nicolas Tentoni, Martin I. Lapidus, Veronica A. Peuchot, Fernando J. Vazquez, Marcelo M. Serra Tags: Letter to the Editors-in-Chief Source Type: research